WGS on XNAS, Health Care, GeneDx Holdings Corp., job postings
Measures activity, not value. Not investment advice.
Shares fell 34% in one month and 66% in a year while 22% of the shares are sold short.
GoodRevenue up 15% to $460.8M over 12 months; latest quarter up 5.4%
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $123.1M, net loss $12.3M.
31 Dec 2021RevenueNet incomeNet losstallest bar $308.8M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$123.1M
-$12.3M
30 Jun 2026
$114.4M
-$17.7M
31 Mar 2026
$102.3M
-$63.3M
31 Dec 2025
$121.0M
-$17.7M
30 Sep 2025
$116.7M
-$7.6M
30 Jun 2025
$102.7M
$10.8M
31 Mar 2025
$87.1M
-$6.5M
31 Dec 2024
$95.6M
$5.4M
30 Sep 2024
$76.9M
-$8.3M
30 Jun 2024
$70.5M
-$29.2M
31 Mar 2024
$62.4M
-$20.2M
31 Dec 2023
$57.4M
-$25.8M
30 Sep 2023
$53.3M
-$42.3M
30 Jun 2023
$48.7M
-$46.7M
31 Mar 2023
$43.1M
-$61.0M
31 Dec 2022
$61.4M
-$308.8M
30 Sep 2022
$83.2M
-$77.6M
30 Jun 2022
$36.2M
-$85.7M
31 Mar 2022
$53.9M
-$76.9M
31 Dec 2021
$57.8M
-$40.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$460.8M
$402.2M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+15%
+15%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$111.0M
$2.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$3.78
$0.09
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
68.7%
69.6%
48.0%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-21.6%
2.5%
1.7%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-24.1%
0.5%
1.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-41.4%
4.7%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
$15.5M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$170.1M
$155.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$150.0M
$54.8M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$20.1M (net cash)
-$100.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.61
0.52
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$8.16
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
62.8
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
3.0
1.7
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
2.9
1.6
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.6
3.3
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$1.8M
bought $0, sold $1.8M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.7%
215 13F filers vs 221
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
33.7M shares held by 13F filers (30 Sep 2026) of 30.0M outstanding (2 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
22%
6.6M shares sold short (30 Oct 2026) of 30.0M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.3
6.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+8.8%
6.0M shares sold short in the report before, 6.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
65%
65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
15
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+5.4%
$123.1M vs $116.7M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+327%
$10.1M vs $2.4M (quarter ended 30 Jun 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$350K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
16
16 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.3×
16 articles in the last 7 days; its usual week has 3.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 6.3M, 1.7× a year earlier
New lobbying issue
Price $45.46 on 20 Nov 2026, -66% over 12 months (12-month range $34.51 to $167.51)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $91.2M in the last 12 months (the 12 months before: -$95.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $123.1M in the latest quarter, +5.4% on a year earlier.Capital spending per quarter. Capital spending $10.1M in the latest quarter, +327% on a year earlier.Institutional holders (13F filers). 215 13F filers reported holding it in the latest 13F quarter, -15% on a year earlier.Lobbying spend. Lobbying spend: $350K published in the last 12 months, +119% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Mar 2020: $46.7M; public on 15 Mar 2022
Quarter ended 30 Jun 2020: $30.1M; public on 15 Mar 2022
Quarter ended 31 Dec 2020: $64.0M; public on 15 Mar 2022
Quarter ended 31 Mar 2021: $64.2M, +38% on a year earlier; public on 15 Mar 2022
Quarter ended 30 Jun 2021: $47.0M, +56% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Dec 2021: $57.8M, -9.6% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $53.9M, -16% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $36.2M, -23% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $83.2M, +93% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $61.4M, +6.1% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $43.1M, -20% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $48.7M, +35% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $53.3M, -36% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $57.4M, -6.4% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $62.4M, +45% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $70.5M, +45% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $76.9M, +44% on a year earlier; public on 30 Oct 2024
Quarter ended 31 Dec 2024: $95.6M, +67% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $87.1M, +40% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $102.7M, +46% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $116.7M, +52% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $121.0M, +27% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $102.3M, +17% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $114.4M, +11% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $123.1M, +5.4% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $6.8M; public on 15 Mar 2022
Quarter ended 31 Mar 2021: $2.1M; public on 13 May 2022
Quarter ended 30 Jun 2021: $1.2M; public on 16 Aug 2022
Quarter ended 31 Dec 2021: $5.1M, -25% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $1.4M, -34% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.4M, +10% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $2.2M, +119% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $2.2M, -57% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $2.8M, +102% on a year earlier; public on 9 Aug 2023
Quarter ended 31 Dec 2023: $2.4M, +9.7% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $443K; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $1.4M, -51% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $646K; public on 30 Oct 2024
Quarter ended 31 Dec 2024: $3.0M, +28% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $6.1M, +1284% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $2.4M, +75% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $6.2M, +855% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $4.3M, +43% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $6.5M, +5.3% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $10.1M, +327% on a year earlier; public on 4 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 105; public on 14 Feb 2022
31 Mar 2022 report: 102; public on 16 May 2022
30 Jun 2022 report: 106; public on 15 Aug 2022
30 Sep 2022 report: 92; public on 14 Nov 2022
31 Dec 2022 report: 85; public on 14 Feb 2023
31 Mar 2023 report: 78; public on 15 May 2023
30 Jun 2023 report: 54; public on 14 Aug 2023
30 Sep 2023 report: 50; public on 14 Nov 2023
31 Dec 2023 report: 46; public on 14 Feb 2024
31 Mar 2024 report: 57; public on 15 May 2024
30 Jun 2024 report: 83; public on 14 Aug 2024
30 Sep 2024 report: 132; public on 14 Nov 2024
31 Dec 2024 report: 193; public on 14 Feb 2025
31 Mar 2025 report: 217; public on 15 May 2025
30 Jun 2025 report: 219; public on 14 Aug 2025
30 Sep 2025 report: 252; public on 14 Nov 2025
31 Dec 2025 report: 276; public on 17 Feb 2026
31 Mar 2026 report: 237; public on 15 May 2026
30 Jun 2026 report: 221; public on 14 Aug 2026
30 Sep 2026 report: 215; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $22K published
Quarter from 1 Apr 2022: $42K published
Quarter from 1 Jul 2022: $25K published
Quarter from 1 Jul 2025: $80K published
Quarter from 1 Oct 2025: $80K published
Quarter from 1 Jan 2026: $80K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $80K published
Quarter from 1 Oct 2026: $110K published
What is unusual now
Made public in the last 90 days: it had 6.3M shares sold short in the 14 Aug 2026 report, 1.7× the same report last year; it also had 6.0M shares sold short in the 31 Aug 2026 report, 1.7× the same report last year. 3 sharp changes in all.
Short interest spike: had 6.3M shares sold short in the 14 Aug 2026 report, 1.7× the same report last year Public on 26 Aug 2026.
15 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 27%, Customer success & support 13%, Test, quality & reliability 13%, Data & analytics 7%.
Reported lobbying spend: $110K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
24 Aug 2026
New
Michael Best Strategies LLCfor Genedx
TRICARE decision to not pay for genome/exnome sequencing testing for DoD personnel and family members.Defense, Health issues, Insurance
Cavarocchi Ruscio Dennis Associates, L.L.C.for Mount Sinai Genomics, Inc. (D/B/A Sema4)
companion diagnostics at FDA, no bill # Verifying Accurate Leading-Edge IVCT Development (VALID) Act, coverage and reimbursement of molecular diagnostics.Health issues
Two or more unrelated kinds of records unusual within 30 days
19 Nov 2024confirmed
Confirmed across sources Institutional holdings and Short interest and volume
GeneDx(WGS): saw 49 13F filers open a new position in the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it had 2.6M shares sold short in the 31 Oct 2024 report, 3.3× the same report last year. Two unrelated kinds of activity within 21 days.
Short interest and volume: Short interest spike, became public on 25 Oct 2024
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
Short interest and volume: Short interest spike, became public on 13 Nov 2024
The quarter ended 30 Sep 2024 against the 8 quarters before it.
this quarterearliernormal: 11.5See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2024
GeneDx had 2.4M shares sold short in the 15 Oct 2024 report, 3.1× the same report last year.
This period
2.4M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
223K
How far from its usual level
+4.0
Same report last year
766K
History used
641 days
the 15 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
GeneDx saw 49 13F filers open a new position in the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
This period
49 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
11.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+5.6
Same quarter last year
5
History used
1,188 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 11.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2024
GeneDx had 2.6M shares sold short in the 31 Oct 2024 report, 3.3× the same report last year.
This period
2.6M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
226K
How far from its usual level
+4.4
Same report last year
779K
History used
657 days
the 31 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
18 Nov 2026Filings change
filed a director or officer change: CEO Katherine Stueland agreed to step down, effective on Cunningham's start (by Dec 15, 2026); Everett Cunningham named CEO, Class II director.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
9634638
11 Sep 2026Short interest and volume change
had 6.0M shares sold short in the 31 Aug 2026 report, 1.7× the same report last year.
Same report last year: 3.6M; its normal report is 3.7M.
See the evidence
This period
6.0M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
288K
How far from its usual level
+5.3
Same report last year
3.6M
History used
1,326 days
the 31 Aug 2026 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.3M shares sold short in the 14 Aug 2026 report, 1.7× the same report last year.
Same report last year: 3.8M; its normal report is 3.7M.
See the evidence
This period
6.3M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
250K
How far from its usual level
+7.0
Same report last year
3.8M
History used
1,309 days
the 14 Aug 2026 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 31 Jul 2026 report, 1.6× the same report last year.
Same report last year: 3.6M; its normal report is 3.6M.
See the evidence
This period
5.8M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
239K
How far from its usual level
+6.1
Same report last year
3.6M
History used
1,295 days
the 31 Jul 2026 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 15 May 2026 report, 1.4× the same report last year.
Same report last year: 3.5M; its normal report is 3.6M.
See the evidence
This period
4.9M (the 15 May 2026 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
134K
How far from its usual level
+3.6
Same report last year
3.5M
History used
1,218 days
the 15 May 2026 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $6.2M on capital projects in the quarter ended 30 Sep 2025, 9.6× the same quarter last year.
Same quarter last year: $646K; its normal quarter is $2.4M.
See the evidence
This period
$6.2M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$849K
How far from its usual level
+3.0
Same quarter last year
$646K
History used
1,734 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $2.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 3.7M shares sold short in the 13 Jun 2025 report, 3.3× the same report last year.
Same report last year: 1.1M; its normal report is 2.3M.
See the evidence
This period
3.7M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
258K
How far from its usual level
+3.9
Same report last year
1.1M
History used
882 days
the 13 Jun 2025 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $6.1M on capital projects in the quarter ended 31 Mar 2025, 14× the same quarter last year.
Same quarter last year: $443K; its normal quarter is $999K.
See the evidence
This period
$6.1M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$999K
Typical spread (median absolute deviation)
$943K
How far from its usual level
+3.7
Same quarter last year
$443K
History used
1,551 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $999K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 65 13F filers open a new position in the quarter ended 31 Dec 2024, 9.3× the same quarter last year.
Same quarter last year: 7; its normal quarter is 13.5.
See the evidence
This period
65 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
6
How far from its usual level
+5.8
Same quarter last year
7
History used
1,280 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 49 13F filers open a new position in the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it had 2.6M shares sold short in the 31 Oct 2024 report, 3.3× the same report last year. Two unrelated kinds of activity within 21 days.
See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2024
GeneDx had 2.4M shares sold short in the 15 Oct 2024 report, 3.1× the same report last year.
This period
2.4M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
223K
How far from its usual level
+4.0
Same report last year
766K
History used
641 days
the 15 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
GeneDx saw 49 13F filers open a new position in the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
This period
49 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
11.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+5.6
Same quarter last year
5
History used
1,188 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 11.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2024
GeneDx had 2.6M shares sold short in the 31 Oct 2024 report, 3.3× the same report last year.
This period
2.6M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
226K
How far from its usual level
+4.4
Same report last year
779K
History used
657 days
the 31 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2024Institutional holdings change
saw 49 13F filers open a new position in the quarter ended 30 Sep 2024, 9.8× the same quarter last year.
Same quarter last year: 5; its normal quarter is 11.5.
See the evidence
This period
49 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
11.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+5.6
Same quarter last year
5
History used
1,188 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 11.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 2.6M shares sold short in the 31 Oct 2024 report, 3.3× the same report last year.
Same report last year: 779K; its normal report is 1.1M.
See the evidence
This period
2.6M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
226K
How far from its usual level
+4.4
Same report last year
779K
History used
657 days
the 31 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.4M shares sold short in the 15 Oct 2024 report, 3.1× the same report last year.
Same report last year: 766K; its normal report is 1.1M.
See the evidence
This period
2.4M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
223K
How far from its usual level
+4.0
Same report last year
766K
History used
641 days
the 15 Oct 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 36 13F filers open a new position in the quarter ended 30 Jun 2024, 3.0× the same quarter last year.
Same quarter last year: 12; its normal quarter is 11.5.
See the evidence
This period
36 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
11.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+3.7
Same quarter last year
12
History used
1,096 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 11.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.2M shares sold short in the 15 Feb 2024 report, 82% below the same report last year.
Same report last year: 6.6M; its normal report is 769K.
See the evidence
This period
1.2M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
769K
Typical spread (median absolute deviation)
78K
How far from its usual level
+3.8
Same report last year
6.6M
History used
398 days
the 15 Feb 2024 report24 earlier reportsnormal: 769K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 98 entries; narrow the window or the kind of data to see older ones.
Not listed: 280 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001818331
Ticker
WGS
Domain
genedx.com
Employer name
genedx
Hq location
CT|STAMFORD|06902 (1 unverified)
Lobbying client
genedx, sema4 formerly known as mount sinai genomics inc d b a sema4
Name
CM Life Sciences, Inc., GeneDx Holdings Corp., GeneDx, LLC, Sema4 Holdings Corp. and 1 more
Wikipedia
GeneDx
DOL H-1B labor condition applications and PERM certifications12 data points11 May 2026 to 6 Jul 2026
Federal lobbying disclosures (LDA)8 records, 79 data points1 Jan 2018 to 30 Sep 2026
SEC Form 13F institutional holdings198 data points30 Jun 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)107 records14 Aug 2020 to 18 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)492 data points31 Dec 2018 to 2 Nov 2026
SEC Form 4 insider transactions234 records, 564 data points2 Nov 2021 to 18 Sep 2026
FINRA short interest (twice monthly)276 data points13 Jan 2023 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)1942 data points10 Jan 2023 to 20 Nov 2026
Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026